CARDIOLOGY, PHARMACOLOGY, THERAPEUTICS
A thienopyridine type platelet inhibitor, which reduces platelet aggregation by irreversibly binding to P2Y12 receptors, inhibiting ADP–induced platelet aggregation more rapidly, more consistently, and to a greater extent than clopidogrel in normal individuals and in those with coronary artery disease. Prasugrel reduces death from cardiovascular causes, nonfatal myocardial infarction–MI, or nonfatal stroke.
Contraindications Active bleeding–e.g., peptic ulcer, evolving MI or stroke.
Adverse effects Hyper- and hypotension, atrial fibrillation, bradycardia, chest pain, peripheral oedema, thrombotic thrombocytopenic purpura, headache, dizziness, hypercholesterolaemia/hyperlipidaemia, epistaxis
Brand name Effient
References Product literature, Lilly